# Adaptimmune Therapeutics plc (ADAP)

Source: https://www.quantisnow.com/company/ADAP
Generated: 2026-11-09T20:51:36.382Z

- Ticker: ADAP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2015
- Website: adaptimmune.com

## About

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

## Latest ADAP news and filings

- 2025-11-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-adaptimmune-therapeutics-plc-6281859)
- 2025-11-13 13:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-adaptimmune-therapeutics-plc-6276295)
- 2025-11-13 12:30 UTC [SEC Form 15-12G filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-adaptimmune-therapeutics-plc-6276120)
- 2025-10-28 20:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adaptimmune-therapeutics-plc-6247848)
- 2025-10-28 20:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adaptimmune-therapeutics-plc-6247835)
- 2025-10-28 20:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-adaptimmune-therapeutics-plc-6247831)
- 2025-10-28 20:05 UTC [SEC Form POS AM filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-adaptimmune-therapeutics-plc-6247803)
- 2025-10-28 11:30 UTC [SEC Form 25 filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-25-filed-by-adaptimmune-therapeutics-plc-6246914)
- 2025-10-20 11:50 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6238082)
- 2025-10-20 11:40 UTC [Adaptimmune Announces Delisting from Nasdaq](https://www.quantisnow.com/insight/adaptimmune-announces-delisting-from-nasdaq-6238067)
- 2025-10-09 01:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hill Christopher James](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hill-christopher-james-6228065)
- 2025-09-26 20:30 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6213145)
- 2025-09-12 20:27 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6199428)
- 2025-09-08 20:05 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-leadership-update-financial-6193238)
- 2025-09-03 21:00 UTC [SEC Form 4] [Chief Financial Officer Wood Gavin sold $950 worth of Ordinary Shares with a nominal value of GBP0.001 per share (96,000 units at $0.01), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-wood-gavin-sold-950-worth-of-ordinary-6188468)
- 2025-09-02 12:00 UTC [SEC Form 144] [SEC Form 144 filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-adaptimmune-therapeutics-plc-6184901)
- 2025-08-29 22:25 UTC [SEC Form 4] [Chief Operating Officer Bertrand William C Jr sold $2,091 worth of Ordinary Shares with a nominal value of GBP0.001 per share (207,000 units at $0.01), decreasing direct ownership by 17% to 986,352 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-bertrand-william-c-jr-sold-2091-worth-6184287)
- 2025-08-29 22:24 UTC [SEC Form 144] [SEC Form 144 filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-adaptimmune-therapeutics-plc-6184285)
- 2025-08-29 20:30 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-leadership-update-financial-6183952)
- 2025-08-19 23:07 UTC [SEC Form 4] [Director Behbahani Ali sold $229,172 worth of Ordinary Shares with a nominal value of 0.001 GBP per share (19,500,000 units at $0.01) (SEC Form 4)](https://www.quantisnow.com/insight/director-behbahani-ali-sold-229172-worth-of-ordinary-shares-with-6172500)
- 2025-08-19 22:53 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-adaptimmune-therapeutics-plc-6172486)
- 2025-08-19 22:32 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-adaptimmune-therapeutics-plc-6172466)
- 2025-08-15 20:30 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-leadership-update-financial-6168548)
- 2025-08-15 20:24 UTC [SEC Form 144] [SEC Form 144 filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-adaptimmune-therapeutics-plc-6168490)
- 2025-08-15 20:23 UTC [SEC Form 144] [SEC Form 144 filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-adaptimmune-therapeutics-plc-6168484)
- 2025-08-14 20:31 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6166588)
- 2025-08-13 11:47 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-adaptimmune-therapeutics-plc-6162063)
- 2025-08-13 11:37 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-results-of-operations-6162050)
- 2025-08-13 11:30 UTC [Adaptimmune Reports Q2 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/adaptimmune-reports-q2-financial-results-and-provides-business-update-6162039)
- 2025-08-07 20:30 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-leadership-update-financial-6154349)
- 2025-07-31 21:02 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-termination-of-a-6141620)
- 2025-07-30 22:20 UTC [SEC Form 4] [Large owner Ecor1 Capital, Llc sold $6,890,236 worth of Ordinary Shares (64,052,538 units at $0.11) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-ecor1-capital-llc-sold-6890236-worth-of-ordinary-6139296)
- 2025-07-29 11:36 UTC [Analyst Downgrade] [Adaptimmune Therapeutics downgraded by H.C. Wainwright](https://www.quantisnow.com/insight/adaptimmune-therapeutics-downgraded-by-hc-wainwright-6135400)
- 2025-07-28 11:37 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-entry-into-a-6133678)
- 2025-07-28 11:30 UTC [Dividends] [Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds](https://www.quantisnow.com/insight/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-tecelra-6133670)
- 2025-07-17 20:30 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-other-events-6123990)
- 2025-06-26 11:50 UTC [Analyst Downgrade] [Adaptimmune Therapeutics downgraded by Mizuho with a new price target](https://www.quantisnow.com/insight/adaptimmune-therapeutics-downgraded-by-mizuho-with-a-new-price-target-6099795)
- 2025-05-29 20:05 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-submission-of-matters-6063061)
- 2025-05-13 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Adaptimmune Therapeutics plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-adaptimmune-therapeutics-plc-6035796)
- 2025-05-13 11:35 UTC [SEC Form 8-K] [Adaptimmune Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adaptimmune-therapeutics-plc-filed-sec-form-8-k-results-of-operations-6034664)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ADAP
- Earnings history: https://www.quantisnow.com/earnings/ADAP
- Dividend history: https://www.quantisnow.com/dividends/ADAP
- Insider transactions: https://www.quantisnow.com/insiders/ADAP
- Options chain: https://www.quantisnow.com/options/ADAP
- SEC 8-K filings only: https://www.quantisnow.com/company/ADAP/8-k
- RSS and alerts for ADAP: https://www.quantisnow.com/docs/rss-feeds.md